Other
Translational Research in Oncology-U.S
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 1(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT03830918Phase 1Active Not Recruiting
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Role: collaborator
NCT04553770Phase 2Recruiting
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Role: collaborator
All 2 trials loaded